ByteBrief
We're a portrait publication through and through. Turn your phone back and your briefing picks up right where you left it.
(We tried widescreen once. It wasn't us.)
1 story in the last 7 days
The latest insilico medicine news, distilled by AI into sharp ~100-word summaries. ByteBrief tracks insilico medicine across dozens of tech sources and brings you only what matters, updated hourly. Tap any story for the full brief, or open the original source.
Insilico Medicine nominated ISM9077, a potential first-in-class Target Y inhibitor, as a preclinical candidate for ocular diseases, inflammatory disorders, and aging. The AI-empowered pipeline-in-a-drug option advances the company's drug discovery efforts.
Summaries by ByteBrief